Pfizer Asks for Formal U.S. Approval of Oral COVID Treatment Paxlovid | Top News

by cloudnewsmag
0 views

(Reuters) – Pfizer Inc said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).

That is basically consistent with the drug’s current EUA, which Pfizer said covers 50% to 60% of the U.S. population, citing estimates from the U.S. Centers for Disease Control and Prevention.

Data from a study in Israel earlier this month showed Paxlovid reduced COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older, but was not found to prevent severe illness among younger adults.

More than 1.6 million courses of Paxlovid have been administered in the United States, according to data from the Department of Health and Human Services.

(Reporting by Michael Erman; Editing by Bill Berkrot)

Related Posts

%d bloggers like this: